Zai Lab (09688) rose more than 4%, as of the time of publication, rose by 4.06%, at 20.25 Hong Kong dollars, with a turnover of 25.3939 million Hong Kong dollars.
According to the Securities Times APP, Zai Lab (09688) rose more than 4%, as of the time of publication, rose by 4.06%, at 20.25 Hong Kong dollars, with a turnover of 25.3939 million Hong Kong dollars.
On the news front, recently, zai lab's partner novocure (NVCR.US) announced that the U.S. Food and Drug Administration (FDA) has approved the use of Optune Lua in combination with PD-1/PD-L1 inhibitors or pemetrexed, for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) who have disease progression during or after platinum-based therapy.
